Boehringer Ingelheim to Develop and Commercialize Biota’s HCV Candidate in Deal Worth $102M
Nucleoside analogues are focus of collaboration.!--h2>
Biota Holdings entered into a worldwide research collaboration and licensing agreement with Boehringer Ingelheim to develop and commercialize Biota's nucleoside analogues designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
Under the terms of the agreement, Biota is eligible to receive payments up to $102 million based on products achieving certain clinical, regulatory, and commercialization milestones, including an initial technology access fee and research support. In addition, Biota would receive royalties on future sales of licensed products marketed by Boehringer Ingelheim.
Biota is responsible for drug discovery research and Boehringer Ingelheim is responsible for worldwide development of potential compounds and their commercialization. Biota and Boehringer Ingelheim will be equally represented on the joint research committee to oversee and coordinate the activities of the program.